Evotec Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Evotec kazanç ve gelirin sırasıyla yıllık 72.5% ve 11.6% oranında artacağı tahmin edilmektedir. EPS'nin yıllık 75.6% oranında büyümesi beklenmektedir. Özkaynak kârlılığının 3 yıl içinde 3.4% olacağı tahmin edilmektedir.

Anahtar bilgiler

72.5%

Kazanç büyüme oranı

75.6%

EPS büyüme oranı

Life Sciences kazanç büyümesi	26.5%
Gelir büyüme oranı	11.6%
Gelecekteki özkaynak getirisi	3.4%
Analist kapsamı	Good
Son güncelleme	25 Oct 2024

Gelecekteki son büyüme güncellemeleri

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Recent updates

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Nov 05

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 17

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 08

Kazanç ve Gelir Büyüme Tahminleri

XTRA:EVT - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (EUR Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
12/31/2026	1,038	22	51	151	9
12/31/2025	910	-35	-4	78	10
12/31/2024	805	-151	-288	-53	10
6/30/2024	788	-171	-246	-55	N/A
3/31/2024	777	-91	-224	-12	N/A
12/31/2023	781	-84	-180	36	N/A
9/30/2023	821	-95	-191	-17	N/A
6/30/2023	798	-103	-246	-42	N/A
3/31/2023	800	-116	-39	143	N/A
12/31/2022	751	-176	24	206	N/A
9/30/2022	698	-180	121	297	N/A
6/30/2022	684	2	194	322	N/A
3/31/2022	650	90	58	183	N/A
12/31/2021	618	216	3	122	N/A
9/30/2021	571	247	-58	86	N/A
6/30/2021	541	112	-50	93	N/A
3/31/2021	515	42	-99	20	N/A
12/31/2020	501	6	-54	45	N/A
9/30/2020	485	14	-4	62	N/A
6/30/2020	470	35	0	46	N/A
3/31/2020	462	42	43	82	N/A
12/31/2019	446	38	10	42	N/A
9/30/2019	419	61	1	29	N/A
6/30/2019	404	77	46	74	N/A
3/31/2019	398	94	109	139	N/A
12/31/2018	375	84	128	156	N/A
9/30/2018	370	63	109	135	N/A
6/30/2018	338	31	54	80	N/A
3/31/2018	294	20	N/A	19	N/A
12/31/2017	264	23	N/A	11	N/A
9/30/2017	215	28	N/A	64	N/A
6/30/2017	193	35	N/A	73	N/A
3/31/2017	178	36	N/A	74	N/A
12/31/2016	165	28	N/A	67	N/A
9/30/2016	160	18	N/A	5	N/A
6/30/2016	148	6	N/A	-6	N/A
3/31/2016	144	17	N/A	-2	N/A
12/31/2015	128	17	N/A	16	N/A
9/30/2015	119	12	N/A	19	N/A
6/30/2015	104	11	N/A	23	N/A
3/31/2015	93	-4	N/A	9	N/A
12/31/2014	89	-7	N/A	-4	N/A
9/30/2014	85	-29	N/A	6	N/A
6/30/2014	89	-25	N/A	2	N/A
3/31/2014	86	-27	N/A	1	N/A
12/31/2013	86	-25	N/A	7	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: EVT önümüzdeki 3 yıl içerisinde kârlı hale gelmesi öngörülüyor; bu da tasarruf oranından ( 0.8% ) daha hızlı bir büyüme olarak değerlendiriliyor.

Kazançlar ve Piyasa: EVT önümüzdeki 3 yıl içerisinde karlı hale gelmesi öngörülüyor ki bu da ortalama piyasa büyümesinin üzerinde kabul ediliyor.

Yüksek Büyüme Kazançları: EVT önümüzdeki 3 yıl içinde karlı hale gelmesi bekleniyor.

Gelir ve Pazar: EVT şirketinin gelirinin (yıllık 11.6% ) German pazarından (yıllık 5.5% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: EVT şirketinin gelirinin (yıllık 11.6% ) yıllık 20% oranından daha yavaş büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: EVT 'nin Özsermaye Getirisi'nin 3 yıl içinde düşük olması tahmin ediliyor ( 3.4 %).

Evotec Gelecekteki Büyüme

Future kriter kontrolleri 4/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Consensus EPS estimates fall by 77%

Recent updates

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) 32% Share Price Climb

Price target decreased by 22% to €10.65

Consensus EPS estimates fall by 13%

Evotec SE Announces Change in Management Board, Effective 01 October 2024

Price target decreased by 11% to €13.64

Consensus EPS estimates fall by 69%

Evotec SE (ETR:EVT) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

Consensus EPS estimates fall by 77%

Evotec SE (ETR:EVT) Stock's 45% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Evotec SE Updates Earnings Guidance for the Fiscal Year 2024

We Think Evotec (ETR:EVT) Has A Fair Chunk Of Debt

Price target decreased by 7.0% to €19.26

Aurobac Therapeutics, founded by Boehringer Ingelheim, bioMerieux and Evotec, Names Scientific Advisory Board

Evotec SE to Report Nine Months, 2024 Results on Nov 08, 2024

Evotec SE, Annual General Meeting, Jun 10, 2024

Evotec SE announced delayed 20-F filing

Full year 2023 earnings: EPS misses analyst expectations

Evotec SE Provides Earnings Guidance for the Year 2024

Evotec SE Welcomes Aurélie Dalbiez as Chief People Officer, Effective 15 June 2024

Evotec SE to Report Fiscal Year 2023 Results on Apr 24, 2024

Investors Aren't Entirely Convinced By Evotec SE's (ETR:EVT) Revenues

Price target decreased by 7.5% to €23.00

These 4 Measures Indicate That Evotec (ETR:EVT) Is Using Debt Reasonably Well

Price target decreased by 7.6% to €23.67

Price target decreased by 8.3% to €24.88

Evotec SE to Report Q1, 2024 Results on May 22, 2024

Price target decreased by 9.1% to €27.14

A Piece Of The Puzzle Missing From Evotec SE's (ETR:EVT) Share Price

Evotec SE Announces Zhejiang Jingxin Pharmaceutical Co., Ltd Receives Approval for EVT201 in China

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

New minor risk - Share price stability

Evotec SE to Report Nine Months, 2023 Results on Nov 08, 2023

We Think Evotec (ETR:EVT) Can Stay On Top Of Its Debt

Second quarter 2023 earnings released: €0.084 loss per share (vs €0.16 loss in 2Q 2022)

Evotec SE (XTRA:EVT) acquired remaining 50% stake in NephTera Gmbh from Vifor (International) AG for €1.65 million.

Evotec SE Provides Revenue Guidance for the Full Year 2023

Evotec SE Revises Earnings Guidance for the Fiscal Year 2023

Evotec (ETR:EVT) Has A Somewhat Strained Balance Sheet

Evotec SE, Annual General Meeting, Jun 20, 2023

Is There An Opportunity With Evotec SE's (ETR:EVT) 37% Undervaluation?

Price target decreased by 8.1% to €24.93

Price target decreased by 9.8% to €24.73

Does Evotec (ETR:EVT) Have A Healthy Balance Sheet?

Evotec SE Appoints Laetitia Rouxel as Member of the Management Board, Effective 01 April 2023

Price target decreased to €26.72

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Evotec SE Reaffirms Earnings Guidance for the Full Year 2022

Price target decreased to €30.94

Consensus forecasts updated

Evotec Launches PanOmics Data Analysis Platform PanHunter At Bio-IT World

Price target decreased to €32.50

Evotec SE (XTRA:EVT) agreed to acquire Central Glass Germany GmbH from Central Glass Co., Ltd. (TSE:4044) for €1.

Consensus forecasts updated

Consensus EPS estimates have been upgraded.

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Evotec SE Revises Revenue Guidance for the Full Year 2022

Consensus forecasts updated

Evotec (ETR:EVT) Seems To Use Debt Quite Sensibly

Now 20% undervalued

Evotec SE (XTRA:EVT) completed the acquisition of Rigenerand S.R.L. from Xyence Capital SGR and others.

Now 22% undervalued after recent price drop

Evotec Se Appoints Camilla Macapili Languille as New Member of Supervisory Board

Now 22% undervalued after recent price drop

Evotec SE (XTRA:EVT) agreed to acquire Rigenerand S.R.L. for €25 million.

Investor sentiment improved over the past week

Is Now The Time To Look At Buying Evotec SE (ETR:EVT)?

Evotec SE Confirms Revenue Guidance for 2022

Is Evotec (ETR:EVT) A Risky Investment?